These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3436638)

  • 21. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
    Rachamim N; Jaffe CL
    J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production and characterization of monoclonal antibodies recognizing a common 57-kDa antigen of Leishmania species.
    Nejad-Moghaddam A; Abolhassani M
    Iran Biomed J; 2009 Oct; 13(4):245-51. PubMed ID: 19946351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease.
    Gicheru MM; Olobo JO; Anjili CO
    Exp Parasitol; 1997 Feb; 85(2):109-16. PubMed ID: 9030661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility.
    Mitchell GF; Handman E
    Aust J Exp Biol Med Sci; 1983 Feb; 61(Pt 1):11-25. PubMed ID: 6870673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
    Bhowmick S; Mazumdar T; Sinha R; Ali N
    J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.
    Alexander J; Kaye PM
    Clin Exp Immunol; 1985 Sep; 61(3):674-82. PubMed ID: 3907906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brazilian Leishmania stocks phenotypically similar to Leishmania major.
    Momen H; Grimaldi G; Pacheco RS; Jaffe CL; McMahon-Pratt D; Marzochi MC
    Am J Trop Med Hyg; 1985 Nov; 34(6):1076-84. PubMed ID: 3834794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB/c mice.
    Rostamian M; Sohrabi S; Kavosifard H; Niknam HM
    J Microbiol Immunol Infect; 2017 Apr; 50(2):160-166. PubMed ID: 26066544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous leishmaniasis serodiagnosis by immunoperoxidase assay.
    Halevy D; Sarov B; Sarov I; el-On J
    Isr J Med Sci; 1990 Sep; 26(9):485-90. PubMed ID: 2228558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis.
    Anand S; Madhubala R
    Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An experimental vaccine providing heterologous protection for Leishmania species in murine model.
    Bebars MA; el Serougi AO; Makled KM; Mikhael EM; Abou Gamra MM; el Sherbiny M; Mohareb AW; Mohammed EA
    J Egypt Soc Parasitol; 2000 Apr; 30(1):137-56. PubMed ID: 10786026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes.
    Ali N; Afrin F
    J Parasitol; 1997 Feb; 83(1):70-5. PubMed ID: 9057699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S; Vasishta RK; Arora SK
    Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L3T4+ T cells promoting susceptibility to murine cutaneous leishmaniasis express the surface marker Ly-24 (Pgp-1).
    Moll H; Scollay R
    Eur J Immunol; 1989 Feb; 19(2):307-14. PubMed ID: 2467816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.